CPT code 0264T identifies an autologous bone marrow injection procedure in which already harvested bone marrow is prepared and injected into muscle tissue to treat advanced peripheral artery disease and similar ischemic conditions. The code captures a biologic, minimally invasive therapy aimed at improving limb perfusion and reducing the need for major amputation in patients with end-stage peripheral vascular disease. Nationally, this code matters as payers and health systems assess coverage, clinical utility, and appropriate site-of-service for novel cellular therapies.

Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical intent of the code, typical sites of service, and which payers commonly appear in coverage discussions for procedures of this type. The publication also outlines where to look for benchmarks and policy updates, summarizes the clinical context for use in limb salvage and ischemia management, and flags areas where additional coding, clinical, or policy information is needed. Data not available in the input is noted where applicable, including specific coverage policies, utilization benchmarks, and associated ICD-10 diagnoses.